Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
New Strong Sell Stocks for April 2nd
Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst
Ally Bridge Group NY LLC Buys New Shares in Eupraxia Pharmaceuticals Inc. $EPRX
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
Eupraxia Pharmaceuticals Announces Proposed Public Offering
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
Wall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a Bet
Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
Eupraxia Pharmaceuticals Inc. (EPRX) Upgraded to Buy: Here's Why
Eupraxia Pharmaceuticals Inc. (EPRX) is a Great Momentum Stock: Should You Buy?
Wall Street Analysts Believe Eupraxia Pharmaceuticals Inc. (EPRX) Could Rally 85.12%: Here's is How to Trade
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option
Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares
Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Announces CFO Succession
Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
Eupraxia Pharmaceuticals Strengthens Senior Management Team
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo